Amphetamines are the second most highly abused illicit drugs worldwide, yet there is no pharmacological treatment for amphetamine abuse and dependence. Preclinical studies and, more recently, human studies, suggest that the opioid receptor antagonist, naltrexone, might be useful in the treatment of amphetamine abuse. Naltrexone, an opioid receptor antagonist, is currently used for the treatment of alcohol dependence. The aim of this study was to explore the ability of naltrexone to modify selfadministration of amphetamine or ethanol in rhesus monkeys. Monkeys were trained to respond to intravenous injections of either D-amphetamine (0.003 mg/kg/injection) or ethanol (0.05 g/kg/injection) on a fixed ratio 30 schedule. Naltrexone (0.01-1 mg/kg) was administered intramuscularly 30 min before the start of treatment test sessions. Naltrexone dose-dependently decreased both amphetamine and ethanol self-administration. These findings support the potential use of naltrexone as therapy for amphetamine and polydrug abuse.
Introduction
Approximately 1% of the world population report abuse of either illicit and/or prescribed amphetamines (e.g. Adderall; Substance Abuse and Mental Health Services Administration [SAMHSA], 2009; United Nations Office on Drugs and Crime [UNODC], 2009) . Despite this number being greater than that for heroin and cocaine combined, to date, there is no approved pharmaceutical therapy for the treatment of amphetamine abuse.
Drug abuse and dependence often are treated with agonists (e.g. methadone) that activate the same receptors stimulated by the particular drug of abuse (e.g. heroin). Although proven useful in the clinic, this approach may be limited by the addictive properties of the treatment drugs themselves, and being limited for treating dependence to specific drugs.
Receptor antagonists, conversely, might be useful for treating dependence to drugs from different classes. For instance, opioid receptor antagonists attenuate the rewarding effects of both opiates and alcohol in rats (e.g. Roberts and Bennett, 1993; Jimenez-Gomez and Shahan, 2007) . This has been extended to the clinic, where naltrexone has been effective in reducing the use of heroin in detoxified, compliant individuals , and treating alcohol dependence (O'Malley et al., 2002) .
Opioid receptor antagonists also may be useful for treating amphetamine abuse and dependence. In rodents, opioid antagonists impact the neurochemical and behavioral effects of amphetamine. For instance, naloxone pretreatments decrease amphetamine-induced dopamine release in the nucleus accumbens and striatum, and amphetamineinduced increase in locomotor activity in rats (Schad et al., 1995) . More recently, naltrexone decreased reinstatement of amphetamine seeking in rats (Haggkvist et al., 2009) . In humans, naltrexone decreased the reported subjective effects of amphetamine and amphetamine consumption in amphetamine-dependent individuals seeking treatment (Jayaram-Lindström et al., 2008a , 2008b . Together, these findings suggest that opioid receptor antagonists such as naltrexone may be useful in treating amphetamine abuse. No preclinical study to date, however, has investigated whether naltrexone decreases behavior maintained by amphetamine self-administration.
The aim of this study was to assess the effects of naltrexone on D-amphetamine and ethanol self-administration in rhesus monkeys. The use of rhesus monkeys is beneficial when assessing the potential therapeutic value of naltrexone given the extensive drug self-administration literature with this species, and the neuropharmacological and neurochemical similarities of nonhuman primates and humans (Weerts et al., 2007) .
Methods

Subjects
Five adult rhesus monkeys (one female, four males) were used. Three monkeys had earlier ethanol self-administration experience, and one had experience with opioid antagonists. Monkeys were fitted with a chronic, indwelling catheter (Moxmed, Portage, Wisconsin, USA) surgically implanted in the jugular, femoral, or brachial vein. Catheters passed subcutaneously to an exit site at the intrascapular region of the monkey's back. Here, the catheter is connected through a flexible tether to the outside rear of the housing cage to an infusion pump. Monkeys wore a protective jacket attached to the flexible tether to keep the catheter-tether connection in place.
Water was freely available at all times. Monkeys were fed twice per day with Purina monkey chow, approximately 2 h before and after the daily experimental session. Fresh fruit and enrichment toys were also provided daily.
This study was conducted in Association for Assessment and Accreditation of Laboratory Animal Care accredited facilities and the experimental protocol was approved by the University of Michigan Committee for Use and Care of Animals.
Apparatus
Experimental sessions were conducted in the individual housing cages, which were custom built with three solid stainless steel walls and a front barred wall (Research Equipment Co., Bryan, Texas, USA). The caging system was constructed with two cages (top and bottom) each. Cages were arranged in a large room, allowing visual access to other monkeys. Each cage was 76.2 Â 83.8 Â 91.4 cm (W Â H Â D). Three response levers (BRS-LVE, Beltsville, Maryland, USA) were located on a side panel, mounted 25.4 cm above the barred floor. A 2.5-cm diameter cue light was located above each lever. Only the rightmost lever, right and center cue lights were used for this experiment. Drug infusions were delivered with pump speed of 1 cc per 5 s by a roller pump (Watson-Marlow, Falmouth, UK).
Programing and recording of experimental events was controlled with Med Associates software (St Albans, Vermont, USA) and interfacing connected to a computer in an adjacent room.
Procedure
Monkeys had extensive earlier experience in drug selfadministration studies and required no preliminary training. A baseline of intravenous D-amphetamine (0.003 mg/kg/ injection) or ethanol (0.05 g/kg/injection) self-administration was established. During once daily, 90-min afternoon sessions, a red stimulus light was illuminated above the right lever signaling drug availability. Drug deliveries were arranged according to a fixed ratio 30 plus timeout 10-s schedule of drug reinforcement. Thirty responses on the active right lever turned off the red light and turned on a green light above the center lever and the infusion pump. A 10-s time-out period followed each infusion, during which all lights were extinguished and responses had no consequence. The red light was then turned on and drug was again available.
Once a stable baseline of drug self-administration was established, determined by three consecutive sessions with no increasing or decreasing trend in responding, the effects of naltrexone (0.01-1.0 mg/kg) were evaluated. The 0.1 or 0.3 mg/kg dose was tested first, with other doses tested in ascending or descending order. A single dose of naltrexone was delivered intramuscularly 30 min before the beginning of the drug self-administration session. At least three sessions separated each naltrexone pretreatment, contingent on a return to baseline levels of responding.
Drugs D-amphetamine sulfate (Abbott laboratories, Chicago, Illinois, USA), ethanol (Pharmco, Brookfield, Connecticut, USA), and naltrexone hydrochloride (provided by the National Institute on Drug Abuse, Bethesda, Maryland, USA) were dissolved in 0.9% saline.
Data analysis
A linear mixed model with compound symmetry (SPSS, 17.0.2, PASW Statistics, IBM Corporation, Somers, NY, USA) was used, allowing analysis of repeated-measures data sets with missing values (e.g. not all subjects are exposed to all doses). The test of least significant difference was used for pairwise comparisons. Statistical analyses were considered significant when P value is less than 0.05.
Results
Pretreatments with naltrexone dose-dependently decreased amphetamine [F(5,25.48) = 3.29, P < 0.05] and ethanol [F(5,34 .98) = 3.38, P < 0.05] self-administration. Figure 1 shows the average effect of naltrexone pretreatment on response rates (top) and number of injections earned per session (bottom). For amphetamine (n = 3) and ethanol (n = 4) self-administration, the 0.3 and 1 mg/kg doses of naltrexone significantly decreased response rates and injections earned per session.
Given the disparity in control levels of self-administration between the two agents, with higher response rates for amphetamine, response rates during naltrexone pretreatment sessions were transformed to proportion of control. By normalizing the levels of responding, the relative potency of naltrexone could be assessed. Figure 2 shows the proportion of control responses per minute during amphetamine and ethanol sessions as a function of naltrexone dose. Naltrexone decreased responding for amphetamine to the same extent as it decreased responding for ethanol, indicating similar potency [F(1,10.26) = 0.36, not significant].
Discussion
It has been reported that naltrexone decreases the rewarding effects of self-administered alcohol and opiates (e.g. Roberts and Bennett, 1993; Jimenez-Gomez and Shahan, 2007) . This experiment found that pretreatment with naltrexone dose-dependently decreased responding for amphetamine infusions to the same extent that it decreased responding for ethanol infusions. These findings, along with the studies of Jayaram-Lindström et al. (2008a, 2008b) showing that naltrexone reduced the subjective effects, craving, and consumption of amphetamine in humans, suggest that naltrexone should be considered further as a therapy for treating amphetamine abuse and dependence.
One of the benefits of using naltrexone for treating drug abuse is its ability to decrease the rewarding effects of a variety of drugs. In this experiment, naltrexone decreased responding for different drugs at doses reported earlier to decrease oral and intravenous ethanol self-administration in rhesus monkeys (Williams et al., 1998) . Thus far, naltrexone has been useful for treating single-drug abuse or dependence; however, little is known about its usefulness for treating polydrug abuse. Given that most individuals who abuse drugs report intake of more than one drug class (e.g. heroin and cocaine; Leri et al., 2003) , it would be of interest to investigate the effectiveness of naltrexone in treating polydrug abuse. Williams et al. (1998) found that the effects of naltrexone were not surmountable with increases in ethanol dose, suggesting that the mechanism through which naltrexone decreases ethanol self-administration, and perhaps also amphetamine self-administration, differs from typical opioid-agonist/antagonist interaction. It has been suggested that decrease in dopaminergic responses to drugs of abuse produced with opioid receptor antagonists is responsible for the reduction in the rewarding effects of nonopioid drugs (Di Chiara and Imperato, 1988) . It is also possible, however, that this reduction is a result of nonopioidergic aversive effects of naltrexone. The specific mechanism has yet to be elucidated.
Oral naltrexone has been useful in treating alcohol dependence (Srisurapanont and Jarusuraisin, 2005) , but its success has been limited by problems with medication noncompliance. Sustained-release formulations of naltrexone circumvent this problem and show promise for long-term success of the treatment of individuals dependent on opiates and alcohol Soyka and Rösner, 2008) . Given these findings, the use of sustained-release formulation of naltrexone for treating amphetamine abuse and dependence also should be evaluated.
